The Journal of Urology
Volume 182, Issue 1 , Pages 118-124, July 2009

Factors Predicting Prostatic Biopsy Gleason Sum Under Grading

Division of Urologic Surgery and Duke Prostate Center; Department of Surgery, Duke University Medical Center, Durham, North Carolina

Received 7 November 2008 published online 18 May 2009.

Purpose

We determined clinical factors affecting the under grading of biopsy Gleason sum compared with prostatectomy pathology and developed a model predicting the probability of under grading.

Materials and Methods

We analyzed a cohort of 1,701 patients treated for prostate cancer at our institution between 1988 and 2007 with complete biopsy and pathological data available. Patients with a biopsy Gleason sum of 7 or less were included in our analysis. Cases were categorized as under graded or not under graded by comparing biopsy and radical prostatectomy Gleason sums. Logistic regression was used to determine the predictors of under grading based on clinical variables (race, age at diagnosis, body mass index, prostate weight, diagnostic prostate specific antigen, biopsy positive-to-total core ratio, maximal cancer percent in positive cores and time from diagnosis to surgery). A nomogram was developed to calculate the probability of under grading. Results were validated using bootstrapping.

Results

Under grading occurred in 46.6% of our cohort. Significant variables predicting under grading were age at diagnosis, biopsy Gleason sum, diagnostic prostate specific antigen, prostate weight, biopsy positive-to-total core ratio and maximal percent of cancer in cores (p <0.05). Nomogram predictive accuracy was 72.4%.

Conclusions

The risk of Gleason sum under grading can be predicted to a satisfactory level using our nomogram. Predicting under grading would improve patient consulting and identify those who should consider repeat biopsy, ultimately enhancing the accuracy of prostate cancer diagnosis.

Key Words: prostate, prostatic neoplasms, biopsy, diagnosis, nomograms

Abbreviations and Acronyms: PSA, prostate specific antigen, TRUS, transrectal ultrasound

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Study received Duke Prostate Center institutional review board approval.

PII: S0022-5347(09)00548-5

doi:10.1016/j.juro.2009.02.127

The Journal of Urology
Volume 182, Issue 1 , Pages 118-124, July 2009